{"protocolSection": {"identificationModule": {"nctId": "NCT00284856", "orgStudyIdInfo": {"id": "0476-332"}, "secondaryIdInfos": [{"id": "2005_108"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)", "officialTitle": "A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-05"}, "primaryCompletionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-01-31", "studyFirstSubmitQcDate": "2006-01-31", "studyFirstPostDateStruct": {"date": "2006-02-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-04-06", "resultsFirstSubmitQcDate": "2011-04-06", "resultsFirstPostDateStruct": {"date": "2011-05-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a multicenter study to evaluate the efficacy and safety of MK0476 versus placebo in participants with chronic asthma who actively smoke cigarettes."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1640, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Arm 1: Montelukast", "interventionNames": ["Drug: montelukast sodium", "Drug: Comparator: Placebo"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Arm 2: Fluticasone", "interventionNames": ["Drug: Comparator: fluticasone", "Drug: Comparator: Placebo"]}, {"label": "3", "type": "PLACEBO_COMPARATOR", "description": "Arm 3: Placebo", "interventionNames": ["Drug: Comparator: Placebo"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "montelukast 10 mg tablet once daily, 6 month treatment period", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period", "armGroupLabels": ["1", "3"]}, {"type": "DRUG", "name": "Comparator: fluticasone", "description": "fluticasone propionate 250 mcg twice daily, 6 month treatment period", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "montelukast 10 mg Pbo tablet once daily, 6 month treatment period", "armGroupLabels": ["2", "3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Asthma-control Days Over the 6-month Treatment Period", "description": "An asthma-control day, computed from daily diaries, was any day with no unscheduled visit for asthma care, no use of \\> than 2 puffs of \u03b2-agonist, no use of other asthma rescue medication, and no nocturnal awakening. The percentage of asthma-control days was the number of days with asthma-control divided by the total number of days with non-missing values for this endpoint. The patient diary had questions concerning daytime and nighttime symptoms, morning (AM) and evening (PM) peak expiratory flow rate (PEFR), \u03b2-agonist use, asthma attacks and smoking activity.", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Daytime Symptom Score Over a 6-month Treatment Period", "description": "4 daytime symptoms were evaluated daily on a 7-point scale from 0 (best)- 6 (worst). The on-treatment daytime symptom score was computed by averaging over Period II the mean of the 4 daily symptom scores recorded daily in the diary while the baseline daytime symptom score was obtained by averaging the mean of the 4 daily symptom scores across the daily diary entries of the Baseline period (Period I). The change from baseline in mean daytime symptom score is computed as the difference between the mean on-treatment daytime symptom score \\& the mean baseline daytime symptom score.", "timeFrame": "Baseline and 6 months"}, {"measure": "Change From Baseline in Average Morning (AM) PEFR (Peak Expiratory Flow Rate) Over a 6-month Treatment Period", "description": "PEFR measurements were performed daily, in the morning before using any medication. The on-treatment AM PEFR was computed by averaging over Period II (treatment period) the AM PEFR recorded daily in the diary, while the baseline AM PEFR was obtained by averaging the AM PEFR across the daily diary entries of the Baseline Period or Period I (placebo run-in period). The change from baseline in average AM PEFR is computed as the difference between mean on-treatment AM PEFR and mean baseline AM PEFR.", "timeFrame": "Baseline and 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with chronic asthma who actively smoke at least 0.5 to no more than 2 packs of cigarettes a day\n\nExclusion Criteria:\n\n* Participant cannot have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or emphysema.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "23380218", "type": "RESULT", "citation": "Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, Mehta A, Strus JD, Polos PG, Philip G. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013 Mar;131(3):763-71. doi: 10.1016/j.jaci.2012.12.673. Epub 2013 Feb 4."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 1640 participants enrolled in the study, 621 participants were excluded during screening and not randomized. The remaining 1019 participants were randomized.", "groups": [{"id": "FG000", "title": "Montelukast", "description": "Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}, {"id": "FG001", "title": "Fluticasone", "description": "Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months"}, {"id": "FG002", "title": "Placebo", "description": "Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "347"}, {"groupId": "FG001", "numSubjects": "336"}, {"groupId": "FG002", "numSubjects": "336"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "296"}, {"groupId": "FG001", "numSubjects": "286"}, {"groupId": "FG002", "numSubjects": "276"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "50"}, {"groupId": "FG002", "numSubjects": "60"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "22"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "18"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Montelukast", "description": "Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}, {"id": "BG001", "title": "Fluticasone", "description": "Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months"}, {"id": "BG002", "title": "Placebo", "description": "Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "347"}, {"groupId": "BG001", "value": "336"}, {"groupId": "BG002", "value": "336"}, {"groupId": "BG003", "value": "1019"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.7", "spread": "10.4"}, {"groupId": "BG001", "value": "38.4", "spread": "10.7"}, {"groupId": "BG002", "value": "37.9", "spread": "9.9"}, {"groupId": "BG003", "value": "38.0", "spread": "10.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "163"}, {"groupId": "BG001", "value": "147"}, {"groupId": "BG002", "value": "166"}, {"groupId": "BG003", "value": "476"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "184"}, {"groupId": "BG001", "value": "189"}, {"groupId": "BG002", "value": "170"}, {"groupId": "BG003", "value": "543"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Asthma-control Days Over the 6-month Treatment Period", "description": "An asthma-control day, computed from daily diaries, was any day with no unscheduled visit for asthma care, no use of \\> than 2 puffs of \u03b2-agonist, no use of other asthma rescue medication, and no nocturnal awakening. The percentage of asthma-control days was the number of days with asthma-control divided by the total number of days with non-missing values for this endpoint. The patient diary had questions concerning daytime and nighttime symptoms, morning (AM) and evening (PM) peak expiratory flow rate (PEFR), \u03b2-agonist use, asthma attacks and smoking activity.", "populationDescription": "Efficacy analysis was based on the full analysis set (FAS) population which included all participants who had at least 7 days of on-treatment data for the specific endpoint. Thirty three patients were excluded from the FAS (13 on montelukast, 7 on fluticasone and 13 on placebo). One participant in the placebo group did not take study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Montelukast", "description": "Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}, {"id": "OG001", "title": "Fluticasone", "description": "Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months"}, {"id": "OG002", "title": "Placebo", "description": "Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "329"}, {"groupId": "OG002", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.70", "spread": "38.19", "lowerLimit": "40.62", "upperLimit": "49.33"}, {"groupId": "OG001", "value": "53.30", "spread": "39.06", "lowerLimit": "44.86", "upperLimit": "53.53"}, {"groupId": "OG002", "value": "43.84", "spread": "38.08", "lowerLimit": "34.65", "upperLimit": "43.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "5.92", "ciPctValue": "95", "ciLowerLimit": "0.28", "ciUpperLimit": "11.56", "estimateComment": "Estimated Value is difference in least squares mean (montelukast - placebo)"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "10.14", "ciPctValue": "95", "ciLowerLimit": "4.50", "ciUpperLimit": "15.78", "estimateComment": "Estimated value is difference in least squares mean (fluticasone - placebo)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "-4.22", "ciPctValue": "95", "ciLowerLimit": "-9.83", "ciUpperLimit": "1.38", "estimateComment": "Estimated value is difference in least squares mean (montelukast - fluticasone)"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Daytime Symptom Score Over a 6-month Treatment Period", "description": "4 daytime symptoms were evaluated daily on a 7-point scale from 0 (best)- 6 (worst). The on-treatment daytime symptom score was computed by averaging over Period II the mean of the 4 daily symptom scores recorded daily in the diary while the baseline daytime symptom score was obtained by averaging the mean of the 4 daily symptom scores across the daily diary entries of the Baseline period (Period I). The change from baseline in mean daytime symptom score is computed as the difference between the mean on-treatment daytime symptom score \\& the mean baseline daytime symptom score.", "populationDescription": "Efficacy analysis was based on the full analysis set (FAS) population which included all participants who received at least one dose of the randomized double-blind study medication and who had at least 7 days of on-treatment data for the specific endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and 6 months", "groups": [{"id": "OG000", "title": "Montelukast", "description": "Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}, {"id": "OG001", "title": "Fluticasone", "description": "Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months"}, {"id": "OG002", "title": "Placebo", "description": "Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "335"}, {"groupId": "OG001", "value": "329"}, {"groupId": "OG002", "value": "322"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.82", "spread": "1.03", "lowerLimit": "-0.53", "upperLimit": "-0.37"}, {"groupId": "OG001", "value": "1.78", "spread": "0.97", "lowerLimit": "-0.58", "upperLimit": "-0.42"}, {"groupId": "OG002", "value": "1.90", "spread": "0.94", "lowerLimit": "-0.38", "upperLimit": "-0.23"}]}]}, {"title": "Average Change from Baseline During Period II", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "0.70"}, {"groupId": "OG001", "value": "-0.44", "spread": "0.68"}, {"groupId": "OG002", "value": "-0.27", "spread": "0.72"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "-0.15", "ciPctValue": "95", "ciLowerLimit": "-0.25", "ciUpperLimit": "-0.05", "estimateComment": "Estimated value is difference in least squares mean (montelukast - placebo)"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "-0.20", "ciPctValue": "95", "ciLowerLimit": "-0.30", "ciUpperLimit": "-0.10", "estimateComment": "Estimated value is difference in least squares mean (fluticasone - placebo)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "0.05", "ciPctValue": "95", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.15", "estimateComment": "Estimated value is difference in least squares mean (montelukast - fluticasone)"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Average Morning (AM) PEFR (Peak Expiratory Flow Rate) Over a 6-month Treatment Period", "description": "PEFR measurements were performed daily, in the morning before using any medication. The on-treatment AM PEFR was computed by averaging over Period II (treatment period) the AM PEFR recorded daily in the diary, while the baseline AM PEFR was obtained by averaging the AM PEFR across the daily diary entries of the Baseline Period or Period I (placebo run-in period). The change from baseline in average AM PEFR is computed as the difference between mean on-treatment AM PEFR and mean baseline AM PEFR.", "populationDescription": "Efficacy analysis was based on the full analysis set (FAS) population which included all participants who received at least one dose of the randomized double-blind study medication and who had at least 7 days of on-treatment data for the specific endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters/minute", "timeFrame": "Baseline and 6 months", "groups": [{"id": "OG000", "title": "Montelukast", "description": "Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}, {"id": "OG001", "title": "Fluticasone", "description": "Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months"}, {"id": "OG002", "title": "Placebo", "description": "Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "329"}, {"groupId": "OG002", "value": "324"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "363.75", "spread": "112.40"}, {"groupId": "OG001", "value": "354.28", "spread": "101.64"}, {"groupId": "OG002", "value": "347.98", "spread": "99.21"}]}]}, {"title": "Average Change from Baseline During Period II", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.84", "spread": "40.22"}, {"groupId": "OG001", "value": "19.31", "spread": "44.85"}, {"groupId": "OG002", "value": "8.27", "spread": "40.70"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "5.09", "ciPctValue": "95", "ciLowerLimit": "-1.27", "ciUpperLimit": "11.45", "estimateComment": "Estimated value is difference in least squares mean (montelukast - placebo)"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "11.21", "ciPctValue": "95", "ciLowerLimit": "4.85", "ciUpperLimit": "17.58", "estimateComment": "Estimated value is difference in least squares mean (fluticasone - placebo)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Squares Mean Difference", "paramValue": "-6.13", "ciPctValue": "95", "ciLowerLimit": "-12.46", "ciUpperLimit": "0.20", "estimateComment": "Estimated value is difference in least squares mean (montelukast - fluticasone)"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "The population for safety analyses was the All Patients as Treated (APaT) set.\n\nThe set included all randomized participants who took at least one dose of the\n\ndouble-blind study medication. One participant in the placebo group was randomized but did not take treatment. Therefore, participant was not included in the safety analyses.", "eventGroups": [{"id": "EG000", "title": "Montelukast", "description": "Montelukast 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months", "seriousNumAffected": 9, "seriousNumAtRisk": 347, "otherNumAffected": 65, "otherNumAtRisk": 347}, {"id": "EG001", "title": "Fluticasone", "description": "Fluticasone propionate 250 mcg twice daily and Montelukast matching placebo 10 mg tablet once daily at bedtime for 6 months", "seriousNumAffected": 10, "seriousNumAtRisk": 336, "otherNumAffected": 57, "otherNumAtRisk": 336}, {"id": "EG002", "title": "Placebo", "description": "Montelukast matching placebo 10 mg tablet once daily at bedtime and Fluticasone propionate matching placebo 250 mcg twice daily for 6 months", "seriousNumAffected": 11, "seriousNumAtRisk": 335, "otherNumAffected": 72, "otherNumAtRisk": 335}], "seriousEvents": [{"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Dermoid cyst", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 335}]}, {"term": "Autoimmune hepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 335}]}, {"term": "Endometritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 335}]}, {"term": "Salpingo-oophoritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 335}]}, {"term": "Brain herniation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 335}]}, {"term": "Post procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 335}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Facial palsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 5, "numAffected": 2, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 335}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}, {"term": "Abortion induced", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 335}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 30, "numAffected": 23, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 34, "numAffected": 27, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 26, "numAffected": 22, "numAtRisk": 335}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 71, "numAffected": 45, "numAtRisk": 347}, {"groupId": "EG001", "numEvents": 50, "numAffected": 34, "numAtRisk": 336}, {"groupId": "EG002", "numEvents": 95, "numAffected": 57, "numAtRisk": 335}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The SPONSOR must have the opportunity to review all proposed abstracts,\n\nmanuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as\n\nconfidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Austria", "Belgium", "Bulgaria", "Canada", "Chile", "China", "Colombia", "Ecuador", "Egypt", "Estonia", "Finland", "Greece", "Hungary", "India", "Israel", "Korea, Republic of", "Lebanon", "Lithuania", "Malaysia", "Mexico", "Peru", "Philippines", "Poland", "Portugal", "Romania", "Russian Federation", "Slovenia", "South Africa", "Spain", "Turkey", "United Arab Emirates"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}